These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 2224945)

  • 21. [Viewpoint on the methodology of drug trials affecting cognition of elderly patients].
    Allain H; Bernard PM; Dartigues JF; Dérouesné C; Dubois B; Hugonot L; Laurent B; Léger JM; Malauzat D; Michel B
    Encephale; 1994; 20(6):725-39. PubMed ID: 7875107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The "kynurenate test", a biochemical assay for putative cognition enhancers.
    Pittaluga A; Vaccari D; Raiteri M
    J Pharmacol Exp Ther; 1997 Oct; 283(1):82-90. PubMed ID: 9336311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Angiotensin converting enzyme inhibitors as potential cognitive enhancing agents.
    Domeney AM
    J Psychiatry Neurosci; 1994 Jan; 19(1):46-50. PubMed ID: 8148365
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The canine model of human cognitive aging and dementia: pharmacological validity of the model for assessment of human cognitive-enhancing drugs.
    Studzinski CM; Araujo JA; Milgram NW
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Mar; 29(3):489-98. PubMed ID: 15795058
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Soy isoflavones and cognitive function.
    Lee YB; Lee HJ; Sohn HS
    J Nutr Biochem; 2005 Nov; 16(11):641-9. PubMed ID: 16169201
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of nicotinic stimulation on cognitive performance.
    Newhouse PA; Potter A; Singh A
    Curr Opin Pharmacol; 2004 Feb; 4(1):36-46. PubMed ID: 15018837
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnosis of dementia and treatment of Alzheimer's disease. Pharmacologic management of disease progression and cognitive impairment.
    van Reekum R; Simard M; Farcnik K
    Can Fam Physician; 1999 Apr; 45():945-52. PubMed ID: 10216793
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiple central nervous system targets for eliciting beneficial effects on memory and cognition.
    Buccafusco JJ; Terry AV
    J Pharmacol Exp Ther; 2000 Nov; 295(2):438-46. PubMed ID: 11046074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic and prophylactic utility of the memory-enhancing drug donepezil hydrochloride on cognition of patients undergoing electroconvulsive therapy: a randomized controlled trial.
    Prakash J; Kotwal A; Prabhu H
    J ECT; 2006 Sep; 22(3):163-8. PubMed ID: 16957530
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A collaborative approach to targeted treatment development for schizophrenia: a qualitative evaluation of the NIMH-MATRICS project.
    Bromley E
    Schizophr Bull; 2005 Oct; 31(4):954-61. PubMed ID: 16166607
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cognitive dysfunction in neuropsychiatric disorders: selected serotonin receptor subtypes as therapeutic targets.
    Terry AV; Buccafusco JJ; Wilson C
    Behav Brain Res; 2008 Dec; 195(1):30-8. PubMed ID: 18241938
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alcohol-impaired speed and accuracy of cognitive functions: a review of acute tolerance and recovery of cognitive performance.
    Schweizer TA; Vogel-Sprott M
    Exp Clin Psychopharmacol; 2008 Jun; 16(3):240-50. PubMed ID: 18540784
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How similar are fluid cognition and general intelligence? A developmental neuroscience perspective on fluid cognition as an aspect of human cognitive ability.
    Blair C
    Behav Brain Sci; 2006 Apr; 29(2):109-25; discussion 125-60. PubMed ID: 16606477
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Results and prospects of development of neuropharmacology in the department of pharmacology of the Acad. S. V. Anichkov Research Institute of Experimental Medicine, USSR Academy of Medical Sciences].
    Borodkin IuS; Zavodskaia IS; Losev NA; Moreva EV; Sapronov NS
    Vestn Akad Med Nauk SSSR; 1990; (11):16-23. PubMed ID: 2284839
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel therapeutic targets for enteric nervous system disorders.
    De Giorgio R; Barbara G; Furness JB; Tonini M
    Trends Pharmacol Sci; 2007 Sep; 28(9):473-81. PubMed ID: 17764756
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of common anti-epileptic drugs on cognition in schoolchildren with epilepsy.
    Jha S; Kumar V; Mishra VN
    Indian J Physiol Pharmacol; 2001 Oct; 45(4):507-10. PubMed ID: 11883162
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Applying new approaches from cognitive neuroscience to enhance drug development for the treatment of impaired cognition in schizophrenia.
    Carter CS
    Schizophr Bull; 2005 Oct; 31(4):810-5. PubMed ID: 16107584
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An hypothesis on the role of glucose in the mechanism of action of cognitive enhancers.
    Wenk GL
    Psychopharmacology (Berl); 1989; 99(4):431-8. PubMed ID: 2687922
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Taking stock of cognition enhancers.
    Sarter M
    Trends Pharmacol Sci; 1991 Dec; 12(12):456-61. PubMed ID: 1792689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.